High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: A retrospective evaluation

Bone Marrow Transplantation

Volumn 31, Issue 9, 2003, Pages 755-761

  Demirer, T ^a,b   Uysal, V A ^b   Ayli, M ^a,b   Genc, Y ^f   Ilhan, O ^b   Koc, H ^b   Dagli, M ^c   Arat, M ^b   Gunel, N ^d   Fen, T ^c   Dincer, S ^a,b   Ustael, N ^a,b   Yildiz, M ^a,b   Ustun, T ^a,b   Seyrek, E ^e   Ozet, G ^a,b   Muftuoglu, O ^a,b   Akan, H ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c ANKARA ONCOLOGY HOSPITAL   (Turkey)

^d GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^e MERSIN UNIVERSITY   (Turkey)

^f Mersin University Medical School ^*

Author keywords

TMCb Regimen in advanced breast cancer

Indexed keywords

BUSULFAN; CARBOPLATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BLADDER DISEASE; BONE LESION; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN MANIFESTATION; SOFT TISSUE DISEASE; STEM CELL MOBILIZATION; VIRUS PNEUMONIA; VISCERAL METASTASIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; HUMANS; MELPHALAN; MIDDLE AGED; NEOPLASM METASTASIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 12444288470     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703918     Document Type: Article

References (42)

1. Sarosy G, Leyland-Jones B, Soochan P et al. The systemic administration of intravenous melphalan. J Clin Oncol 1988; 6: 1768-1782.
2. Wright JC, Golomb FM, Gumport SL et al. Summary of results with triethylenethiophosphoramide. Ann NY Acad Sci 1958; 68: 937-966.
3. Lemaistre CF, Herqig GP, Herqig RH et al. High-dose thiotepa and autologous bone marrow rescue for the treatment of breast cancer. Breast Cancer Res Treat 1987; 10: 89.
4. Maranichi D. Piana L, Blaise D et al. Phase I-II studies of high-dose alkylating agents in poor risk patients with breast cancer with autologous bone marrow transplant. In: ABMT: Proceedings of the Third International Symposium. Dicke K, Spitzer TR, Jagannath S (eds). University of Texas MD Anderson Hospital: Houston, TX, 1987; 475-480.
5. Corringham R, Gilmore M, Prentice H et al. High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors. Cancer 1983; 52: 1783-1787.
6. Weaver CH, Bensinger WI, Appelbaum FR et al. Phase I study of high-dose busulfan. melphalan, and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.
7. Schiffman K, Bensinger W, Appelbaum F et al. Phase-II of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943-950.
8. Bensinger W, Schiffman K, Holmberg L et al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant 1997; 19: 1183-1189.
9. Eder JP, Elias A, Shea TC et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239-1245.
10. Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651-655.
11. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
12. Holland K, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156-1164.
13. Ayash L, Elias A, Ibrahim J et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 1998; 16: 1000-1007.
14. Demirer T, Ilhan O, Mandel NM et al. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow Transplant 2000; 25: 697-703.
15. Demirer T, Buckner CD, Bensinger WI et al. Peripheral blood stem cell (PBSC) collections after taxol, cyclophosphamide and recombinant human granulocyte-colony-stimulating factor (rhG-CSF). J Clin Oncol 1995; 13: 1714-1719.
16. Demirer T, Buckner CD, Storer B et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte-colony stimulating factor. J Clin Oncol 1997; 15: 684-690.
17. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood progenitor cells following the administration of cyclophosphamide, etoposide and granulocyte-colony stimulating factor: an analysis of 497 patients. Transfusion 1997; 37: 896-903.
18. Rowley SD, Bensinger WI, Gooley T et al. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994; 83: 2731-2736.
19. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
20. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-2049.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Hyrniuk WM. Relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987; 14: 65-74.
23. Broder LE, Tormey DC. Combination chemotherapy of carcinoma of the breast cancer. Cancer Treat Rev 1974; 1: 183-203.
24. Antman K, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
25. Demirer T, Buckner CD, Appelbaum FR et al. High-dose busulfan, and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 1996; 17: 769-774.
26. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
27. Williams SF, Mick R, Desser R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824-1830.
28. Klumpp TR, Mangan KF, Glenn LD et al. Phase II pilot study of high-dose busulfan and CY followed by autologous BM of peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 1993; 11: 337-339.
29. Eder JP, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
30. Dunphy FR, Spitzer G, Buzdar A et al. Treatment of estrogen receptor negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207-1216.
31. Williams SF, Gilewski T, Mick R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-1747.
32. Ayash LJ, Wheeler C, Reich E et al. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
33. Vaughan WP, Reed EC, Kessinger A et al. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant 1994; 13: 619-624.
34. Gutierrez-Delgado F, Holmberg LA, Hooper H et al. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer. Bone Marrow Transplant 2000; 26: 51-59.
35. Antman K, Gale RP. Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med 1988; 108: 570-574.
36. Berry DA, Broadwater G, Klein JP et al. High-dose versus standard dose chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002; 20: 743-750.
37. Lotz JP, Cure H, Janvier M et al. High dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: results of the French protocol PEGASE 04. Proc Am Soc Clin Oncol 1999; 18: 43a.
38. Stadtmauer EA. O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069-1076.
39. Madan B, Broadwater G, Rubin P et al. Improved survival with consolidation high-dose CBP compared with observation followed by transplant at relapse in women with metastatic breast cancer and only bone metastases treated with induction AFM: a phase III prospective randomized comparative trial. Proc Am Soc Clin Oncol 2000; 19: 48a(184).
40. Peters WP, Jones RB, Vredenburgh J et al. A large, prospective, randomized trial of high-dose combination alkylating agent (CBP) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1996; 15: 149a.
41. Crump M, Gluck S, Stewart D et al. Randomized trial of high-dose chemotherapy with autologous peripheral blood stem cell support compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) Clinical Trials Group Study. Proc Am Soc Clin Oncol 2001; 20: 21a.
42. Weaver CH, West WH, Schwartzberg LS et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 1997; 19: 661-670.